Collins Stewart Starts ZIOPHARM Oncology (ZIOP) at Buy; Palifosfamide Poised to be Standard-of-Care in mSTS
Tweet
Share
E-mailGet Alerts ZIOP Hot Sheet
Price: $0.87 --0%
Rating Summary:
6 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 13 | New: 26
Rating Summary:
6 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 13 | New: 26
Join SI Premium – FREE
Collins Stewart initiates coverage on ZIOPHARM Oncology (NASDAQ: ZIOP) with a Buy. PT $9.00.
Collins analyst says, "We are initiating coverage on ZIOP with a Buy and $9 PT given our view that the palifosfamide P3 PICASSO-3 study has a high likelihood of success in font-line metastatic soft tissue sarcoma (mSTS), an orphan cancer. Given positive P2 data (trial stopped early on a 3.4 month PFS benefit), an identically-designed P3 study (except N=424 vs. N=67 in P2) and encouraging physician feedback, we believe the P3 study should meet its PFS endpoint in 2H12, supporting U.S./E.U. accelerated approval in 2014, with OS (co-primary endpoint) in ~2015 supporting full approval."
"Physicians believe palifosfamide could become the standard-of-care (SOC) in mSTS as they expect the drug to show superior safety and at least similar efficacy to the current SOC, ifosfamide, which is not approved for STS and is associated with significant toxicities."
For an analyst ratings summary and ratings history on ZIOPHARM Oncology click here. For more ratings news on ZIOPHARM Oncology click here.
Shares of ZIOPHARM Oncology closed at $4.31 yesterday.
Collins analyst says, "We are initiating coverage on ZIOP with a Buy and $9 PT given our view that the palifosfamide P3 PICASSO-3 study has a high likelihood of success in font-line metastatic soft tissue sarcoma (mSTS), an orphan cancer. Given positive P2 data (trial stopped early on a 3.4 month PFS benefit), an identically-designed P3 study (except N=424 vs. N=67 in P2) and encouraging physician feedback, we believe the P3 study should meet its PFS endpoint in 2H12, supporting U.S./E.U. accelerated approval in 2014, with OS (co-primary endpoint) in ~2015 supporting full approval."
"Physicians believe palifosfamide could become the standard-of-care (SOC) in mSTS as they expect the drug to show superior safety and at least similar efficacy to the current SOC, ifosfamide, which is not approved for STS and is associated with significant toxicities."
For an analyst ratings summary and ratings history on ZIOPHARM Oncology click here. For more ratings news on ZIOPHARM Oncology click here.
Shares of ZIOPHARM Oncology closed at $4.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- B.Riley Starts Weave Communications Inc (WEAV) at Buy
- Macquarie Starts Bursa Malaysia Bhd (BURSA:MK) at Outperform
- Macquarie Starts Sunway Construction (SCGB:MK) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
Collins StewartSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
